Results 151 to 160 of about 4,938,261 (300)

Urticarial vasculitis coexisting with primary myelofibrosis – a case report

Przegląd Dermatologiczny, 2017
Introduction . Urticarial vasculitis is a subtype of cutaneous leukocytoclastic vasculitis. The disease often accompanies systemic disorders, including hematologic malignancies, connective tissue diseases, and infectious diseases, or may be drug-induced.
Radomir Reszke, Adam Reich
doaj   +1 more source

Validation of the WHO-defined 20% circulating blasts threshold for diagnosis of leukemic transformation in primary myelofibrosis

Blood Cancer Journal, 2018
Leukemic transformation is the most dreaded complication in patients with myeloproliferative neoplasms (MPN); overall risk is estimated at 14% for primary myelofibrosis (PMF), 7% for polycythemia vera (PV) and 4% for essential thrombocythemia (ET).
M. Mudireddy, N. Gangat, C. Hanson, R. Ketterling, A. Pardanani, A. Tefferi   +5 more
semanticscholar   +1 more source

Immune and Immune‐Integrated Organoids as NextGeneration Platforms for Disease Modeling

MedComm, Volume 6, Issue 12, December 2025.
This graphical abstract outlines the sources and methods for integrating immune cells into organoids. Immune cells can be derived from peripheral blood, tissues, or differentiated from human‐induced pluripotent stem cells. The immune cells are incorporated into the organoid by using coculture techniques, direct injection, as well as scaffolds and air ...
Kimiya Rashidan, Malaksima Ayadilord, Ali Hazrati, Amirhossein Nazerian, Abbas Shafiee, Seyed Mahmoud Hashemi   +5 more
wiley   +1 more source

Coexistence of primary myelofibrosis and chronic lymphocytic leukemia

Blood and Lymphatic Cancer: Targets and Therapy, 2014
Sonja Burgstaller, Josef Thaler Klinikum Wels-Grieskirchen, Abteilung für Innere Medizin IV, Wels, AustriaAbstract: Coexistence of two hematologic malignancies in one patient is generally a rare phenomenon.
Burgstaller S, Thaler J
doaj  

The impact of JAK2V617F variant allele frequency in MPN patients following PEGylated interferon alpha discontinuation

British Journal of Haematology, Volume 207, Issue 6, Page 2597-2601, December 2025.
Treatment with pegylated interferon α resulted in a molecular response in 91% of patients with an average decrease in JAK2V61F VAF of 48.5% from baseline. In patients that discontinued treatment, the JAK2V617F VAF at the time of treatment discontinuation was the best indicator of durable remission over the 6‐month follow‐up period.
Ryan Brown, Rebekah Bennett, Clare Crean, Andrew Hindley, Julie McGimpsey, Nicholas Cunningham, Aaron Niblock, Suzanne McPherson, Kathryn Boyd, Allister Foy, Ciaren Graham, Graeme Greenfield, Mary Frances McMullin, Mark A. Catherwood   +13 more
wiley   +1 more source

Janus Kinase Inhibitors During Pregnancy and Adverse Drug Reactions: A Pharmacovigilance Disproportionality Analysis in VigiBase

Clinical and Translational Science, Volume 18, Issue 12, December 2025.
ABSTRACT Janus kinase inhibitors (JAKIs) are immunomodulatory drugs used for autoimmune and inflammatory conditions. Their potential impact on pregnancy and fetal development remains a concern due to placental transfer and potential disruption of cytokine and growth factor signaling, with limited human data.
Nazanin Abolhassani, Roberta Noseda, Kim Dao, François R. Girardin, Francesca Bedussi, Alessandro Ceschi, Alice Panchaud, Ursula Winterfeld   +7 more
wiley   +1 more source

No Effect of Immunogenicity on Pharmacokinetics, Efficacy, and Safety of the Oligonucleotide Telomerase Inhibitor Imetelstat in Lower‐Risk Myelodysplastic Syndromes

Clinical and Translational Science, Volume 18, Issue 12, December 2025.
ABSTRACT Imetelstat is a first‐in‐class, 13‐mer oligonucleotide telomerase inhibitor approved in the United States and European Union for the treatment of certain adult patients with lower‐risk myelodysplastic syndromes (LR‐MDS) with red blood cell (RBC) transfusion‐dependent anemia.
Ashley L. Lennox, Fei Huang, Mario González‐Sales, Ying Wan, Libo Sun, Tymara Berry, Faye Feller, Peter N. Morcos   +7 more
wiley   +1 more source

Primary myelofibrosis: current therapeutic options

Revista Brasileira de Hematologia e Hemoterapia
Primary myelofibrosis is a Philadelphia-negative myeloproliferative neoplasm characterized by clonal myeloid expansion, followed by progressive fibrous connective tissue deposition in the bone marrow, resulting in bone marrow failure.
Paula de Melo Campos
doaj   +1 more source

Biomolecular and histological features in pediatric essential thrombocythemia: adequacy of who diagnostic criteria [PDF]

, 2017
Myeloproliferative neoplasms (MPN), Essential Thrombocythemia (ET), Polycythemia Vera (PV) and primary myelofibrosis (PMF), are clonal disorders of the hematopoietic stem cell.
Bertozzi, Irene
core   +1 more source

Primary Myelofibrosis in a Young Girl- A Case Report

, 2023
Homayra Tahseen Hossain, Arfa Rahman, Masudul Alam Mazumder, Mahbub Mayukh Rishad, Quazi Tarikul Islam, Mohammad Zahiruddin   +5 more
openalex   +2 more sources